Actively Recruiting
Risk Evaluation by COronary Imaging and Artificial intelliGence Based fuNctIonal analyZing tEchniques - IV
Led by Ruijin Hospital · Updated on 2025-01-27
200
Participants Needed
1
Research Sites
182 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a single-center, prospective cohort study. The study is designed to identify novel circulating biomarkers for early prediction of high-risk coronary plaques. Patients diagnosed with chronic coronary syndrome (CCS) or non-ST-segment elevation acute coronary syndrome (NSTE-ACS), with marginal lesions or obstructive lesions in major coronary arteries detected by noninvasive coronary CT angiography (CCTA) or invasive coronary angiography (ICA), will be consecutively enrolled. Optical coherence tomography (OCT), with or without other intracoronary imaging modalities such as intravascular ultrasound (IVUS) and near infrared spectroscopy (NIRS), will be performed. Liquid chromatography-mass spectrometry (LC-MS/MS), bioinformatic analysis, and machine learning methods will be performed to characterize plasma proteomic profiles. The cohort will be followed-up every 3 months for 2 years. The association of novel biomarkers with the occurrence of major adverse cardiovascular events (MACEs) will be examined.
CONDITIONS
Official Title
Risk Evaluation by COronary Imaging and Artificial intelliGence Based fuNctIonal analyZing tEchniques - IV
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosed with chronic coronary syndrome (CCS) or non-ST-segment elevation acute coronary syndrome (NSTE-ACS)
- Underwent coronary CT angiography (CCTA) or invasive coronary angiography (ICA) showing marginal lesions (40%-69% diameter stenosis) or obstructive lesions (70% or more diameter stenosis or CT-FFR/FFR less than 0.8) in major coronary arteries
- Received invasive coronary angiography and optical coherence tomography (OCT), with or without intravascular ultrasound (IVUS) and near infrared spectroscopy (NIRS) imaging techniques
You will not qualify if you...
- Percutaneous coronary intervention (PCI) within the past 6 months
- History of myocardial infarction or heart failure
- History of coronary artery bypass graft (CABG)
- Abnormal liver function (alanine aminotransferase [ALT] over 3 times the normal limit) or abnormal kidney function (eGFR 30% or less)
- Familial hypercholesterolemia
- Estimated survival of 1 year or less
- Malignant tumor
- Pregnant, breastfeeding, or planning to give birth within one year
- Poor compliance or inability to complete follow-up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China, 200025
Actively Recruiting
Research Team
X
Xiao Qun Wang, M.D.,Ph.D.
CONTACT
S
Shuo Feng, M.D.,Ph.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here